BNP Screening for PAH in Scleroderma PDF Print E-mail
Tuesday, 24 July 2012 19:41
An elevated level of N-terminal pro-brain natriuretic peptide (NT-proBNP) has a high sensitivity and specificity for pulmonary arterial hypertension in patients with systemic sclerosis (SSc-PAH), Australian rheumatologists and cardiologists have suggested.

They investigated a total of 94 patients with systemic sclerosis in four groups: one with SSc-PAH confirmed by right heart catheterisation, another considered at high risk because of findings on trans-thoracic echocardiography, a group with interstitial lung disease, and a group with no cardiopulmonary complications.

“NT-proBNP was highest in the PAH group compared with the other groups, and higher in the risk group compared with controls,” they said.

The marker was positively correlated with systolic and mean pulmonary artery pressure, pulmonary vascular resistance and mean right atrial pressure.

Further analysis defined thresholds for NT-proBNP and/or results on carbon monoxide pulmonary diffusion tests that should prompt investigation for possible PAH, for example with echocardiography, high-resolution CT, 6-minute walk test, and definitive right heart catheterisation when indicated.

PAH accounted for about 30% of deaths related to systemic sclerosis, the researchers said. In its earliest stages, patients were often asymptomatic or minimally symptomatic but early detection and treatment could delay progression and improve survival.

Annual echocardiography was recommended to screen for early PAH, but this strategy had limitations including technical challenges, insufficient reliability in the presence of coexisting lung disease, poor acoustic windows in some patients, the need for expertise, and issues of cost and resource allocation.

NT-proBNP was released by cardiac myocytes in response to increased ventricular wall stress. The blood test was now widely available given its importance in the diagnosis, prognosis and risk stratification of congestive cardiac failure, they said.

Source: James, T. (2012), "BNP screening for pulmonary arterial hypertension in systemic sclerosis"; Rheumatology Update; original article can be viewed here.

 
More articles :

» Recent Study Shows 32 Million Americans Have Autoantibodies That Target Their Own Tissues

A recent NIH study says more than 32 million people in the United States have autoantibodies, which are proteins produced in the immune system that attack the body's tissues, defining a condition known as . It also looked at the prevalence of the...

» Anticoagulation of Systemic Sclerosis Patients In Question

Australia is in a state of ‘clinical equipoise’ over whether to anticoagulate systemic sclerosis patients with pulmonary hypertension, experts say. And with observational studies showing the treatment is associated with a  fivefold...

» Comprehensive Report on the Global State of Autoimmune Diseases Released

A groundbreaking new report from the (AARDA), examining the current state of autoimmune disease (AD) and its economic and social impact globally and in the U.S., was released today at the National Autoimmune Diseases Summit:  The Global State...

» Enhanced Survival Found With Early Detection of Scleroderma-Associated PAH

Early detection of incident systemic sclerosis–associated enhanced survival in a prospective cohort study of 131 patients from the multicenter PHAROS, according to data presented at the annual meeting of the American College of Rheumatology.The...

» Preliminary Results Show Beneficial Effects of Imatinib in Scleroderma

Imatinib (Gleevec), a drug that has significantly improved survival in chronic myelogenous leukemia and gastrointestinal stromal tumor, is showing beneficial effects on skin and lung manifestations in patients with diffuse cutaneous scleroderma....

» Cancer Drug Shows Promise For Treating Scleroderma

A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with , according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated in a Phase III trial, the gold...